Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
出版年份 2021 全文链接
标题
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
作者
关键词
-
出版物
Lancet Respiratory Medicine
Volume 9, Issue 6, Pages 593-600
出版商
Elsevier BV
发表日期
2021-01-28
DOI
10.1016/s2213-2600(20)30390-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression
- (2020) Daniel Rathkey et al. Journal of Thoracic Oncology
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
- (2019) Maria J Disselhorst et al. Lancet Respiratory Medicine
- Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
- (2019) Marc Ladanyi et al. Genome Medicine
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas
- (2019) Robin Guo et al. Journal of Thoracic Oncology
- PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma
- (2018) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
- (2018) Vasiliki Panou et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of PARP and Immune-Checkpoint Inhibitor Combinations
- (2018) Ross A Stewart et al. CANCER RESEARCH
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes
- (2018) Marta Betti et al. GENES CHROMOSOMES & CANCER
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma
- (2018) Julija Hmeljak et al. Cancer Discovery
- A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair
- (2017) Rossella Parrotta et al. Journal of Thoracic Oncology
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
- (2017) Angela Bononi et al. NATURE
- Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells
- (2015) Shuhei Hakiri et al. CANCER SCIENCE
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- (2015) Lee M Krug et al. LANCET ONCOLOGY
- Germline Mutations in BAP1 Impair Its Function in DNA Double-Strand Break Repair
- (2014) I. H. Ismail et al. CANCER RESEARCH
- PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
- (2013) Giulia Pinton et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
- (2013) H. Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma
- (2011) Sara Busacca et al. JOURNAL OF PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More